Drug intelligence / Profile preview

Shiva 101

Development stage: Unknown
Lead developer: CorMedix

Overview

Shiva 101 is a pharmaceutical product under development by CorMedix Inc. and Shiva Biomedical, LLC. It is designated as a "License Product" and was slated to initiate patient dosing in a pivotal trial by March 31, 2012. CorMedix holds the final decision-making authority regarding its development and has the option to discontinue its development. The specific mechanism of action and primary indication are not detailed in the available context.

Beyond the preview

Go deeper on Shiva 101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Shiva 101.

Explore the full profile